{"id":"azd9773","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Gastrointestinal disorders"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"MyD88 is a critical adaptor protein in toll-like receptor (TLR) and interleukin-1 receptor signaling pathways that drive innate immune activation and inflammation. By selectively inhibiting MyD88, AZD9773 suppresses downstream inflammatory cytokine production and immune cell activation. This mechanism is intended to reduce pathological inflammation in autoimmune and inflammatory diseases.","oneSentence":"AZD9773 is a selective inhibitor of myeloid differentiation primary response 88 (MyD88) that blocks innate immune signaling to reduce inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:57:46.734Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE)"},{"name":"Other autoimmune/inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT01145560","phase":"PHASE2","title":"A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-10","conditions":"Severe Sepsis, Septic Shock","enrollment":300},{"nctId":"NCT01144624","phase":"PHASE2","title":"A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-07","conditions":"Severe Sepsis, Septic Shock","enrollment":20},{"nctId":"NCT00615017","phase":"PHASE2","title":"AZD9773 Dose Escalation Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Severe Sepsis","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CytoFab™"],"phase":"phase_2","status":"active","brandName":"AZD9773","genericName":"AZD9773","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD9773 is a selective inhibitor of myeloid differentiation primary response 88 (MyD88) that blocks innate immune signaling to reduce inflammatory responses. Used for Systemic lupus erythematosus (SLE), Other autoimmune/inflammatory conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}